Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Breno Oliveira
|
| gptkbp:country |
gptkb:Brazil
|
| gptkbp:formerName |
Hypermarcas
|
| gptkbp:founded |
2001
|
| gptkbp:headquarters_location |
gptkb:São_Paulo
|
| https://www.w3.org/2000/01/rdf-schema#label |
Hypera Pharma
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:market |
gptkb:Latin_America
|
| gptkbp:notableBrand |
gptkb:Finn
gptkb:Neo_Química gptkb:Rennie gptkb:Cefaclor gptkb:Cefotaxima Olla Addera D3 Alivium Atroveran Benegrip Biotônico Fontoura Cefadroxila Cefalexina Cefazolina Cefepima Cefixima Ceftriaxona Cefuroxima Celestamine Cewin Cimegripe Coristina D Dipirona Monoidratada Doril Engov Epocler Estomazil Gelol Jontex Maxsulid Miosan Neosaldina Predsim Rinosoro Tandrilax Vitasay 50+ Xantinon Zero-Cal |
| gptkbp:products |
prescription drugs
consumer health products OTC drugs |
| gptkbp:publiclyTraded |
yes
|
| gptkbp:stockExchange |
gptkb:B3
|
| gptkbp:stockSymbol |
HYPE3
|
| gptkbp:website |
https://www.hypera.com.br/
|
| gptkbp:bfsParent |
gptkb:Neo_Química
|
| gptkbp:bfsLayer |
7
|